https://novaprd-lb.newcastle.edu.au/vital/access/manager/Index ${session.getAttribute("locale")} 5 Parp inhibitors and haematological malignancies—friend or foe? https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:48905 Wed 19 Apr 2023 16:25:55 AEST ]]> Quality assurance audit: a prospective non-randomised trial of chemotherapy and radiotherapy for osteolymphoma (TROG 99.04/ALLG LY02) https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:7373 Sat 24 Mar 2018 08:40:16 AEDT ]]> Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:7699 Sat 24 Mar 2018 08:33:33 AEDT ]]> Involved-field radiotherapy for patients with mantle cell lymphoma https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:26649 Sat 24 Mar 2018 07:26:50 AEDT ]]> COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:47968 Mon 13 Feb 2023 15:58:53 AEDT ]]> Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignancies https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:54765 Mon 11 Mar 2024 15:01:55 AEDT ]]> A prospective, multicenter study of involved-field radiation therapy with autologous stem cell transplantation for patients with hodgkin lymphoma and aggressive non-hodgkin lymphoma (ALLG HDNHL04/TROG 03.03) https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:45459 Fri 28 Oct 2022 14:22:16 AEDT ]]>